Open Access

Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy

  • Authors:
    • Yaowen Zhang
    • Shangwen Dong
    • Ruiping Xu
    • Yanping Yang
    • Zhiyong Zheng
    • Xiaojing Wang
    • Runchuan Ren
    • Ronggang Sun
    • Ming Li
    • Haijun Yang
    • Yuting Huang
    • Fuyou Zhou
    • Anping Zheng
  • View Affiliations

  • Published online on: February 24, 2017     https://doi.org/10.3892/ol.2017.5780
  • Pages: 2549-2556
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Identification of biomarkers for predicting radiosensitivity would be useful for administering individualized radiotherapy (RT) to patients with esophageal cancer. The aim of the present study was to evaluate the association between cyclooxygenase-2 (COX-2), X-ray repair cross complementing group 1 (XRCC1), ras association domain family 1 (RASSF1) protein expression, clinicopathological characteristics, radiosensitivity and survival rate in 76 patients with esophageal squamous cell carcinoma (ESCC) who were treated with RT. Positive expression of COX‑2, XRCC1 and RASSF1 was identified by immunohistochemistry in 81.6, 52.6 and 59.2% of ESCC cases, respectively. Negative COX‑2 expression was associated with tumor (T) stage, node (N) stage, clinical stage and complete response (P<0.05), but not with gender, age, tumor location, differentiation degree, lesion length, progression‑free survival (PFS) or overall survival (OS; P>0.05). XRCC1 expression was not associated with the clinicopathological features of ESCC, response to RT, PFS or OS. Positive RASSF1 expression was associated with the clinical stage, response to RT, PFS and OS (P<0.05), but not with gender, age, tumor location, T stage, N stage, differentiation degree or the lesion length (P>0.05). In the subgroup analysis, RASSF1 positive/XRCC1 negative expression was correlated with a longer median OS and PFS (P<0.05). Multivariate analyses revealed that the tumor response and RASSF1 expression were significant prognostic factors. Therefore, positive RASSF1 expression is associated with ESCC RT sensitivity, and may be a useful independent prognostic factor for ESCC.

Related Articles

Journal Cover

April 2017
Volume 13 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, Y., Dong, S., Xu, R., Yang, Y., Zheng, Z., Wang, X. ... Zheng, A. (2017). Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy. Oncology Letters, 13, 2549-2556. https://doi.org/10.3892/ol.2017.5780
MLA
Zhang, Y., Dong, S., Xu, R., Yang, Y., Zheng, Z., Wang, X., Ren, R., Sun, R., Li, M., Yang, H., Huang, Y., Zhou, F., Zheng, A."Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy". Oncology Letters 13.4 (2017): 2549-2556.
Chicago
Zhang, Y., Dong, S., Xu, R., Yang, Y., Zheng, Z., Wang, X., Ren, R., Sun, R., Li, M., Yang, H., Huang, Y., Zhou, F., Zheng, A."Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy". Oncology Letters 13, no. 4 (2017): 2549-2556. https://doi.org/10.3892/ol.2017.5780